<DOC>
	<DOC>NCT00805025</DOC>
	<brief_summary>Over the 70-day study period, eligible patients visited the study clinic every 2 weeks (total of 6 visits) and received a 28-day course of aztreonam for inhalation solution (AZLI). The Quality of Life-Bronchiectasis (QOL-B) questionnaire was completed at several time points during the study, in additional to pulmonary function testing and other standard procedures.</brief_summary>
	<brief_title>Evaluation of the Quality of Life Questionnaire-Bronchiectasis (QOL-B) in Patients With Bronchiectasis</brief_title>
	<detailed_description />
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Aztreonam</mesh_term>
	<criteria>Written informed consent prior to any studyrelated procedures Ability to read and understand the English language Bronchiectasis confirmed by CT scan of the chest Previous treatment with antibiotics for bronchiectasis Documented history of positive sputum culture for a gramnegative organism within 5 years Positive sputum culture for a gramnegative organism at first visit (Day 14) Hospitalization or hemoptysis &gt; 30 mL within 14 days of first visit (Day 14) Antibiotic use for respiratory symptoms within 14 days of first visit (Day 14), excluding chronic, stable azithromycin use Change in corticosteroid or bronchodilator regimen within 14 days of first visit (Day 14) Forced expiratory volume in 1 second (FEV1) &lt; 25% predicted approximately 15 minutes following use of a bronchodilator at first visit (Day 14) Cigarette smoking within 6 months of first visit (Day 14)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>